Which Trial Can Actually Move Can-Fite in 2026-2027?
Can-Fite’s next headline is likely to come from pancreatic cancer in Q3 2026, but the catalyst that can truly change how the story is judged sits in LIVERATION for HCC. Psoriasis is heavy and important, but it carries a tougher proof burden, while MASH remains a real option without a disclosed hard date.
The main article mapped the pipeline. This follow-up ranks the milestones, because not every clinical update carries the same weight.
The answer upfront: if the question is which program prints the first headline, pancreatic cancer is the answer. If the question is which trial can truly change how Can-Fite will be judged in 2026-2027, the answer runs first through LIVERATION in HCC, and only then through psoriasis.
The distinction is not just about timing. It is about the type of proof on offer. Pancreatic cancer is an open-label Phase IIa study with 20 evaluable patients, a primary endpoint of safety, and that primary endpoint has already been met. HCC and psoriasis sit inside Phase III programs with explicit regulatory framing and interim analyses set for Q2 2027. That is a different class of test.
The 2026-2027 Catalyst Map
| Program | Current status | Disclosed milestone | What is really being tested | Evidentiary weight for the thesis |
|---|---|---|---|---|
| Pancreatic cancer | Phase IIa, enrollment complete | Top-line efficacy in Q3 2026 | Whether there is something beyond the safety profile already shown | Medium for the headline, lower for a deeper re-rating |
| HCC | LIVERATION Phase III, open for enrollment | Interim analysis in Q2 2027 | Whether the CPB7 survival signal survives in a pivotal setting | The highest |
| Psoriasis | COMFORT Phase III, enrolling | Interim analysis in Q2 2027 | Whether Piclidenoson can hit the Week 16 endpoints the study is built around | High, but less clean |
| MASH | Phase IIb, enrolling | No explicit dated milestone in the table | Whether the program is progressing toward a readout the market can frame | Medium, but without a visible clock |
This chart does not capture the full R&D burden, because salaries, facilities, depreciation, stock compensation, and other indirect costs sit outside the direct-cost table. It still shows where the heavy programs are. Pancreatic cancer is advancing, but it remains a relatively small program. The budget center of gravity is still HCC, MASH, and psoriasis.
Pancreatic Cancer, the Near-Term Headline
This is the first catalyst, not necessarily the decisive one. The January 2026 6-K put pancreatic cancer at the front of the calendar: enrollment was complete, safety was the primary endpoint, and the company was already guiding to top-line efficacy data in Q3 2026. The annual report added another layer: by March 2026 the study had already met its primary safety endpoint, no new safety signals had emerged, and one third of the patients were still alive at the data cut-off, so survival follow-up remained ongoing.
The key point is not just what comes out of the study, but what kind of proof the study can realistically deliver. This is an open-label trial in advanced pancreatic adenocarcinoma after at least one prior line of therapy, with 20 evaluable patients and secondary efficacy endpoints such as ORR, PFS, DCR, DoR, and OS. So even if the readout produces a strong headline, the market will still have to decide whether it is seeing an early clinical signal that justifies expansion, or evidence strong enough to change the company-level thesis.
That is why pancreatic cancer is first and foremost an interpretation event. It can improve tone, extend attention, and reinforce the sense that Namodenoson is generating signals beyond HCC. But as long as safety is the primary endpoint and survival follow-up is still maturing, it is a catalyst that fits a headline more easily than it supports a wholesale reset of the proof ladder.
HCC, the Trial That Can Truly Move the Center of Gravity
This is where the heaviest test sits. The first reason is the study design: LIVERATION is a pivotal, randomized, double-blind, placebo-controlled Phase III trial intended to enroll about 450 HCC patients with CPB7 cirrhosis. The primary endpoint is overall survival. The company also says explicitly that the study is designed to support an NDA in the U.S. and an MAA in Europe. This is no longer a signal-hunting exercise. It is meant to decide whether the old signal is real.
The second reason is the quality of the contradiction already embedded in the program’s history. In Phase II, the primary overall survival endpoint was not met in the full 78-patient population. Yet inside the CPB7 subgroup, Namodenoson showed median OS of 6.8 months versus 4.3 months on placebo, alongside one-year survival of 44% versus 18%. The entire LIVERATION thesis is really built on the idea that this signal was real, but got diluted inside a broader and less suitable population.
That is what makes HCC the most important Can-Fite trial over the next two years. If the Q2 2027 interim shows that the signal survives in Phase III, the company will no longer be judged only as a name with a busy pipeline. It will be judged as a company that can carry a late-stage program toward a genuine regulatory threshold. If the signal does not return, the damage runs deeper than a routine clinical disappointment. It hits the exact program the company itself framed as registration-supportive.
Psoriasis, a Heavy Trial With a Tougher Proof Burden
This is probably the second-most important trial, but it is less clean than HCC. On one hand, this is also a Phase III program, backed by positive FDA and EMA feedback on the registration plan and protocol, with an interim analysis due in Q2 2027. On the other hand, the earlier efficacy record creates a tension that is hard to ignore.
In the earlier psoriasis data, Piclidenoson 3 mg delivered statistically significant improvement versus placebo on PASI 75 at Week 16, 9.7% versus 2.6%. But by Week 32, against Otezla, it was inferior on PASI 75 and PASI 50. The picture improved over time, and by Week 48 the response curve had kept climbing, with PASI 50 in 90% of patients, PASI 90 in 10%, and PDI improvement in 60%. That is a strength, but it is also a point of friction.
The friction comes from the current study design. The co-primary endpoints in Phase III are PASI 75 and an sPGA of 0 or 1, both at Week 16. In other words, the program is not being judged on gradual long-tail improvement. It is being judged on whether it can hit earlier and harder endpoints. That pulls the burden of proof forward precisely where Piclidenoson’s historical profile looked more cumulative than explosive.
There is another reason not to assign psoriasis the same regulatory sharpness as HCC. The company states that the FDA requested two Phase III safety and efficacy studies. So even if the 2027 interim is positive, it does not necessarily close the file. It can raise confidence materially, but it does not automatically make the path simple.
Still, psoriasis cannot be pushed to the side. The program’s direct cost rose from $550 thousand in 2024 to $1.275 million in 2025, more than doubling, which shows the company is meaningfully advancing the project. This is a heavy catalyst. It is simply one that demands more caution in interpretation.
MASH, a Real Option Without a Visible Clock
MASH sits in an odd place in this hierarchy. On one hand, the Phase IIb study is enrolling, it includes 140 subjects with biopsy-confirmed MASH, treatment runs for 36 weeks, and its 2025 direct cost, $1.289 million, is even slightly above psoriasis. The earlier Phase II study also generated encouraging data, including ALT normalization in 36.8% of the 25 mg group versus 10% on placebo, along with a broader set of inflammation and steatosis indicators that moved in the right direction.
On the other hand, in the table of current major projects MASH is still stuck on one phrase, enrolling patients. There is no dated interim, no top-line window, and no clear checkpoint the market can anchor to in 2026-2027. That is exactly why it sits below pancreatic, HCC, and psoriasis in the catalyst ranking. Not because the program looks weak, but because the timing signal is still vague.
The Real Ranking
If the pipeline is ranked by which program can create the first headline, pancreatic cancer comes first. If it is ranked by which program can change the quality of proof around the company, the order flips.
- HCC is the core catalyst because it is the program built around a pivotal Phase III, an overall survival primary endpoint, and an explicit regulatory path.
- Psoriasis is second because it is also a heavy Phase III program, but it arrives with more tension between the historical data and the current Week 16 proof burden, plus the need for two Phase III studies.
- Pancreatic cancer is third because it is the closest event, but also the one that most clearly demands caution against headline temptation.
- MASH is fourth, not because it is unimportant, but because it still lacks the dated milestone that would pull it into the market’s front line.
Conclusion
Can-Fite is not short on milestones. It is short on milestones of the same kind. That is the critical distinction. Pancreatic cancer can generate the first news. HCC can change the level of seriousness with which the market views Namodenoson. Psoriasis can be large, but it has to clear an earlier and tougher proof hurdle than its history makes easy to assume. MASH remains on the board, but for now without the clock that forces the market to take a position.
That also gives the right read on 2026-2027. 2026 looks like a headline-filtering year, led by pancreatic cancer. 2027 looks much more like a proof year. If Can-Fite gets to that point with convincing interim data in HCC, and then in psoriasis, the expectation map around the company changes. If not, even a positive Q3 2026 pancreatic headline may end up looking like noise before the real mass moved.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.